{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.8","upperLimit":"9.7","value":"8.2"},{"groupId":"OG001","lowerLimit":"4.8","upperLimit":"7.0","value":"5.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"description":"Duration of Response (DoR) is defined as the interval from the date of first documentation of objective response (complete response or partial response, according to the mRECIST v1.1) to the date of first documented progression/relapse or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\\^2 intravenously on day 1 every 3 weeks","id":"OG000","title":"Atezolizumab Plus Bevacizumab Plus Chemotherapy"},{"description":"Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\\^2 intravenously on day 1 every 3 weeks","id":"OG001","title":"Bevacizumab Plus Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Patients with objective response","reportingStatus":"POSTED","timeFrame":"From documentation of objective response until the date of first documented progression/relapse or death, up to 52 months.","title":"Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"months"}